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The pathogenesis of pruritus in psoriasis remains unclear. Many possible mediators were implicated to transmit or modulate this
sensation in psoriasis, but none has been clearly proven to be a causative agent of itching. The most often discussed theory men-
tioned the importance of impaired innervations and neuropeptides imbalance in psoriatic skin. Other possible causes of itching
might be increased expression of interleukin 2 or vascular abnormalities. Recent data indicated that pruritus could be also evoked
by opioid system, prostanoids, interleukin 31, serotonin, or proteases. Whether these mechanisms are also involved in pruritus ac-
companying psoriasis requires further investigation. Limited knowledge of pruritus origin in psoriasis is responsible for the lack of
the eﬀective antipruritic treatments for psoriatics. Here, we summarize the current knowledge about the pathogenesis of pruritus
in psoriasis and point out possible directions of future studies aiming the pathogenesis of this symptom in psoriasis.
Copyright © 2007 A. Reich and J. C. Szepietowski. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Local inﬂammatory mechanisms may induce pruritus in
many dermatoses. Mild-to-severe pruritus accompanies nu-
merous inﬂammatory skin disorders including atopic der-
matitis, eczema, psoriasis, or lichen planus. Psoriasis is one
of the most common chronic inﬂammatory skin diseases
with a complex, multifactorial, and still not fully understood
etiopathogenesis.Themainfactorscontributingtothedevel-
opment of psoriatic lesions are genetic predispositions and
immunological disturbances [1, 2]. However, the exacerba-
tion of psoriasis can also be provoked by numerous exoge-
nous factors including stress, smoking, infections, and some
drugs [2]. Pruritus is observed in about 70 to 90% of pa-
tients with psoriasis [3–9], and many of them (at least 30%)
had generalized itching [5, 6]. The mean intensity of this
symptom assessed according to 10 point Visual Analogue
Scale ranged between 3.7–6.4 points [5, 7, 10–12]. This is
lessthantheintensityofpruritusobservedinatopicdermati-
tis or uremic pruritus [13, 14]. However, despite less inten-
sive, pruritus was mentioned by many psoriatic patients as
the most bothersome symptom of psoriasis [5] and it was
clearly documented that pruritus intensity signiﬁcantly cor-
relatedinpsoriaticswithdegreeofqualityoflifeimpairment,
level of stigmatization, as well as the presence and severity of
depressive symptoms [12]. It seems that patients with pruri-
tus suﬀer from more severe psoriasis [4, 6, 8] although some
authors did not ﬁnd a signiﬁcant relationship between pru-
ritus intensity and psoriasis severity [5] .T h ep r e s e n c ea n d
intensity of itching were independent on age, gender, marital
status, family history of psoriasis or atopy, type of psoriasis,
alcohol or smoking habits, duration of the disease, as well as
durationofthelastoutbreakofpsoriasis[5,6,8].Despitethe
highfrequencyofthissymptom,thepathogenesisofpruritus
in psoriasis remains unclear. Here, we reviewed the available
literature data on this symptom in order to summarize our
current knowledge of the origin of pruritus in psoriasis.
2. HISTAMINE
Histamine, one of the major mediators of pruritus, does not
seem to be involved in its development in psoriasis. There
was no correlation between pruritus intensity and histamine
p l a s m al e v e li np s o r i a s i s ,a sw e l la sn od i ﬀerence was ob-
servedinhistamineplasmalevelsbetweenpruriticsandnon-
pruritics patients with psoriasis [10]. In addition, less than
20% of psoriatic subjects claimed that oral antihistaminics
were eﬀective in reducing pruritus [6]. It seems that only se-
dating antihistaminics should be tried in pruritic psoriatics
as they sometimes could be eﬀective due to evoked sedation
[15].Itisgenerallyacceptedthatthehistamineblockadedoes
not prevent pruritus in psoriasis [15].2 Mediators of Inﬂammation
3. NEUROPEPTIDES AND ALTERED
CUTANEOUS INNERVATIONS
The most often discussed theory on pruritus in psoriasis
mentionedtheimportanceofimpairedinnervationandneu-
ropeptides imbalance in psoriatic skin. Interactions between
nerves, neuropeptides, and mast cells, leading to neurogenic
inﬂammation, have also been implicated in another chronic
itchy immunodermatosis: atopic dermatitis [16, 17]. Several
studies demonstrated altered expression and/or distribution
of several neuropeptides and their receptors within various
layersofpsoriaticskin,includingsubstanceP(SP),calcitonin
gene-related peptide (CGRP), vasoactive intestinal peptide
(VIP), somatostatin, β-endorphin, or pituitary adenylate cy-
clase activating polypeptide (PACAP) [17–26]. Neuropep-




also stimulate synthesis and release of many proinﬂamma-
tory cytokines from mast cells, lymphocytes, dendritic cells,
ﬁbroblasts, and keratinocytes, induce expression of vascu-
lar adhesion molecules on endothelium, and exert hyperpro-
liferative eﬀect on keratinocytes [26]. Neuropeptides in the
skin may be released from dermal nerve endings, but they
can also be directly produced by several cell types, for exam-
ple, mastocytes [17].
Nakamura et al. [27] observed that pruritic psoriatic
skin demonstrated signiﬁcantly increased number of nerve
growth factor- (NGF-) immunoreactive keratinocytes, ele-
vated NGF content in the lesional skin, and enhanced ex-
pression of high-aﬃnity receptor for NGF (Trk-A) in the
epidermis and dermal nerve ﬁbres. Moreover, pruritic skin
showed increased number of protein gene product (PGP)
9.5-immunoreactive nerve ﬁbers in the epidermis and in
the upper dermal areas, increased number of SP-containing
nerves in the perivascular areas, as well as decreased ex-
pression of neutral endopeptidase (NEP) in the epidermal
basal layer and in the endothelia of blood vessels [27]. The
pruritus intensity correlated with the number of PGP 9.5-
immunoreactive intraepidermal nerve ﬁbers, the number of
NGF-immunoreactive keratinocytes and the expression level
of TrkA in the epidermis [27]. Nakamura et al. [27] also
found an increased number of mast cells in the papillary der-
misofpruriticpsoriaticskinamongthevariouscellularcom-
ponents examined, including resident cells and inﬁltrating
cells in the skin lesions. Ultrastructural examination showed
that these mast cells possessed degranulating speciﬁc gran-
ulesindicatingthatmastcellsinpruriticpsoriaticskinareac-
tivated.Theparticularlycharacteristicﬁndingofmastcellsin
lesional skin from patients with pruritus was the presence of
freemastcellgranulesincloseappositiontotheperineurium
surrounding unmyelinated nerve ﬁbers. This phenomenon
was never observed in the skin from patients without pru-
ritus [27]. In contrast, Nakamura et al. [27] did not ﬁnd
any diﬀerences between pruritic and nonpruritic psoriatics
regarding the skin expression of brain-derived neurotrophic
factor, neurotrophin-3, VIP, neuropeptides Y (NPY), so-
matostatin, low-aﬃnity receptor for NGF, and angiotensin-
converting enzyme. In another study [8], a hyperprolifera-
tion of small cutaneous nerves was found in the lesional skin
of pruritic psoriatic subjects compared to nonpruritic ones.
Keratinocytes in the psoriatic plaques of patients with pru-
ritus also showed consistently increased expression of SP re-
ceptor, TrkA and CGRP receptor, but the immunoreactivity
for SP, CGRP, VIP, and PACAP was independent on the oc-
currence of pruritus. The expression of NGF, neurotrophin-
4, low-aﬃnity receptor for NGF, PACAP receptor expression,
as well as NEP activity did not diﬀer between pruritus and
nonpruritus group [8]. Interestingly, Remr¨ od et al. [11] did
not ﬁnd any relationship between SP-positive ﬁbers nor cells
andthedegreeofpruritus,buttheanalyzedgroupofpatients
in this study was very small. In addition, the NPY plasma
level was signiﬁcantly decreased in patients with pruritus
compared to patients without pruritus [9]. Plasma levels of
SP, CGRP, and VIP did not diﬀer signiﬁcantly between pru-
ritics and nonpruritics, however, a tendency to lower SP and
VIP plasma levels in patients with pruritus was noted [9].
Moreover,signiﬁcant,negativecorrelationsbetweenpruritus
severity and SP as well as VIP plasma levels were found [9].
It seems probable, that increased expression of neuropep-
tides in the pruritic skin might activate the neuropeptides
degrading enzymes like NEP or angiotensin-converting en-
zyme in a regulatory mechanism. This phenomenon could
lead to the decreased plasma level of selected neuropeptides.
This hypothesis could be supported by the observations that
theproportionbetweenchymase-andtryptase-positivemast
cells was shown to be disturbed in lesional psoriatic skin [28]
aswellaspatientswithpsoriasiswerecharacterizedbyhigher
serum activity of angiotensin-converting enzyme which was
normalized after eﬀective antipsoriatic treatment [29]. In the
study by our group [10] it was noted that CGRP plasma level
was signiﬁcantly elevated in pruritic psoriatic patients com-
pared to healthy subjects, a diﬀerence that was not found be-
tweennonpruriticpsoriaticsandhealthyvolunteers,andthat
CGRP plasma level correlated with itching intensity in some
subgroups of psoriatics. The important role of altered inner-
vations and neuropeptide imbalance in pruritus accompa-
nying psoriasis may also be supported by the observations
that topically applied capsaicin, a potent SP depletory, eﬀec-
tively treated pruritus in psoriatics [30, 31]. Finally, it was
documented that stress-exacerbated pruritus in psoriasis [7]
and neuropeptides seem to be good candidates for linking
nervous system and skin [17]. It could be hypothesized that
increased innervations in the skin of psoriatic patients with
pruritus may lead to a lower threshold for pruritic stimuli
compared to patients without pruritus. Additionally, pruri-
tus might be evoked by the release of selected neuropeptides
from dermal nerve endings and cells during stress, but this
hypothesis still requires further investigations (Table 1).
4. CYTOKINES
Concerning the role of cytokines in pruritus in psoria-
sis, Nakamura et al. [27] found an increased number of
interleukin (IL)-2 immunoreactive cells in pruritic versus
nonpruritic lesions of psoriasis (Table 1). There were no
signiﬁcant diﬀerences in the expression of other cytokinesA. Reich and J. C. Szepietowski 3
Table 1: Possible mediators involved in itching in psoriasis.
Mediator Comment References
Histamine Seems not to be involved in pruritus in psoriasis. [6, 10]
NGF
Increased number of NGF-immunoreactive keratinocytes, elevated
NGF content in the lesional skin and enhanced expression of Trk-A
in the epidermis and dermal nerve ﬁbers in psoriatics with pruritus.
[8, 27]
Substance P
Increased number of SP-containing nerves in the perivascular areas of
pruritic psoriatic skin, increased expression of SP receptor in epider-
mis from pruritic psoriatic subjects.
[8, 27, 30, 31]
CGRP Increased expression of CGRP receptors in pruritic psoriatic skin, in-
creased serum level of CGRP in pruritic psoriatic subjects.
[8, 10]
NPY Decreased NPY plasma level in psoriatic patients with pruritus. [9]
VIP/PACAP Negative correlation between pruritus severity and VIP plasma level [9]
IL-2 IncreasednumberofIL-2immunoreactivecellsinpruriticversusnon-





E-selectin Increased density of E-selectin positive venules in psoriatic patients
with pruritus.
[27]
VAP-1 Increased serum concentration of soluble VAP-1 in psoriatic subjects
with pruritus.
[33]
Serotonin Only indirect data suggesting its importance for pruritus in psoriasis. [34]
Opioids Possible mediators, but no studies in psoriasis are available. [35–40]
Prostanoids Possible mediators, but no studies in psoriasis are available. [41, 42]
Proteases Possible mediators, but no studies in psoriasis are available. [43–46]
CGRP:calcitoningene-relatedpeptide,IL:interleukin,NGF:nervegrowthfactor,NPY:neuropeptideY,PACAP:pituitaryadenylatecyclaseactivatingpolypep-
tide, PARs: protease activated receptors, Trk-A: high-aﬃnity receptor for NGF, VAP-1: vascular adhesion protein 1, VIP: vasoactive intestinal peptide.
(interferon (INF)-γ, tumor necrosis factor (TNF)-α,I L - 1 α,
IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, and IL-12) [27]. Recently,
a novel cytokine, IL-31, was suggested to play an impor-
tant role in pruritus in atopic dermatitis, as IL-31 caused the
itch-associated scratching behavior in conventional NC/Nga
mice, an experimental animal model for atopic dermatitis
[32]. Whether this cytokine also participates in pruritus in
psoriasis needs to be determined.
5. VESSELS AND ADHESION MOLECULES
Vascular abnormalities are frequently observed in psoriatic
lesions [33]. It seems that changes of dermal vasculature
may be important in the pathogenesis of pruritus in psori-
asis (Table 1). A marked increase of the density of E-selectin-
positive venules wasfound in psoriatic patients withpruritus
compared to nonpruritic subjects [27]. However, there was
no statistical diﬀerence in the number of vessels immunore-
activeforintercellularcelladhesionmolecule(ICAM)-1,vas-
cular cell adhesion molecule (VCAM)-1, or platelet endothe-
lial cell adhesion molecule (PECAM)-1 in the upper dermis
or in the expression of ICAM-1 in the epidermis [27]. How-
ever,signiﬁcantcorrelationwasobservedbetweentheitching
intensity and the density of E-selectin-immunoreactive ves-
sels [27]. In addition, Madej et al. [33] found an increased
serum concentration of soluble vascular adhesion protein
(VAP)-1 in psoriatic subjects with pruritus compared to pa-
tient free of this symptom.
6. OTHER POSSIBLE MEDIATORS
Despite the lack of solid laboratory data, other mediators
may also play a role in the pathogenesis of pruritus in pso-
riasis (Table 1). They were found to be important in several
pruritic conditions, but have not been investigated in psori-
asis yet.
It could be speculated that neuropeptides in psoriatic
skin may induce expression and/or activity of dermal pro-
teases, and these enzymes acting via protease-activated re-
c e p t o r s( P A R )m i g h tb er e s p o n s i b l ef o rp r u r t i u s[ 43]. Re-
cent ﬁndings suggested that proteases are not only degrad-
ing enzymes, but rather represent a group of mediators com-
municating with nerves, and thereby modulating inﬂamma-
tion, pain, and pruritus [43, 44]. A massive itch behavior was
noted in mice overexpressing epidermal kallikrein-7 [43].
Tryptase and microbial proteases induced itch by the PAR-
2-mediated neurogenic mechanism [43, 45]. Activation of
PAR-2 evoked itching both in mice and in human [43–46].
Because PAR-2 is irreversibly activated by proteases, it might
be a good candidate for the explanation of chronic itch.
Pruritus may be elucidated by the opioid system as well.
It is believed that activation of μ-opioid receptors induces
while activation of κ-opioid receptors alleviates pruritus.4 Mediators of Inﬂammation
A signiﬁcantly altered μ-a n dκ-opioid receptor expression
was observed in the epidermis of patients with atopic der-
matitis, showing mainly downregulation of κ-opioid system
[35, 36]. PUVA treatment, a frequently applied and eﬀective
therapy of atopic dermatitis, was shown to reconstitute the
altered opioid receptor distribution in epidermis of these pa-
tients [36]. Opioids may also induce pruritus acting in cen-
tral nervous system. It was shown that intrathecal adminis-
tration of morphine elicits pruritus and both naloxone and
naltrexone,thepotentμ-opioidreceptorantagonists,reduces
histamine-induced pruritus in atopic dermatitis subjects to
greater extend than antihistaminic drugs [37, 38]. On the
other hand, nalfuraﬁne, a κ-opioid receptor agonist, led to
signiﬁcant reduction of itching in patients with uremic or
cholestatic pruritus [39, 40].
Prostanoids, mainly prostaglandin D2 [41, 42]a n dtr o m -
boxaneA2 [47]orserotonin[48],couldbefurthercandidates
as mediators of pruritus in psoriasis. The importance of the
latter one might be supported by the observations that mir-
tazapine, an antihistaminic drug acting also via noradrener-
genic α2-receptors and 5HT2 and 5HT3 serotonin receptors,
relieved psoriatic itch even in cases of severe pruritus associ-
ated with erythrodermic psoriasis [34].
7. THE ROLE OF CENTRAL NERVOUS SYSTEM
Pruritus causes the desire to scratch the skin and is experi-
enced as a sensation arising in the skin [49]. However, like
all other skin sensations, itch is a product of central nervous
system activities [49]. The itch-selective spinal neurons form
a distinct pathway projecting from lamina I of the spinal
cord to the ventrocaudal part of the nucleus medialis, which
projects to the anterior cingulated and dorsal insular cortex
[49]. Recent studies characterized the supraspinal processing
of itch in humans by diﬀerent imaging techniques. Intrader-
mal injection of histamine in healthy volunteers led to ac-
tivation of anterior cingulate cortex, supplementary motor
area, premotor area, and inferior parietal lobe [50, 51]. Pro-
longed itch stimuli activated a superior frontal gyrus and the
gyrus rectus in both hemispheres as well as in a small area of
theleftanteriorcingulatedgyrus[52].Furtheractivationwas
located in the left temporal pole and some parts of the left
cerebellum [52]. Repetitive scratching induced bilateral ac-
tivation of the secondary somatosensory cortex, insular cor-
tex, inferior parietal lobe, and cerebellum while anterior and
posteriorcingulatedcorticesweredeactivated[53].Themain
limitation of these studies is the observations of healthy sub-
jects. As it was demonstrated by Ishiuji et al. [54], the brain
processing of itch in chronic skin conditions like in atopic
dermatitis is signiﬁcantly diﬀerent than in healthy individu-
als. Therefore, further data are needed to identify the brain
areas responsible for pruritus in patients with chronic itch,
including those having psoriasis.
8. CONCLUSIONS
Summarizing, pruritus is an important symptom of psori-
asis. Despite the fact that several studies have been under-
taken to investigate the pathogenesis of pruritus in psoriasis,
m a n ya s p e c t sh a v en o tb e e ns t u d i e dy e t( Table 1). Therefore,
the pathogenesis of this symptoms is far to be well under-
stood and, as a consequence, the therapy of pruritic psoriatic
patients still remains a big challange for clinicians. We hope
that in the near future new studies will be conducted to bet-
ter characterize and understand this symptom in psoriasis.
We do believe that this progress may facilitate the develop-
ment of new eﬀective antipruritic treatment modalities.
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